Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:John_F._Crowley
|
| gptkbp:focusesOn |
orphan drugs
rare diseases |
| gptkbp:founded |
2002
|
| gptkbp:founder |
gptkb:John_F._Crowley
|
| gptkbp:headquartersLocation |
gptkb:Philadelphia,_Pennsylvania,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amicus Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:keyPerson |
gptkb:John_F._Crowley
Bradley L. Campbell |
| gptkbp:notableProduct |
AT-GAA
Galafold |
| gptkbp:numberOfEmployees |
over 500
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:specializesIn |
enzyme replacement therapies
pharmacological chaperones |
| gptkbp:stockSymbol |
gptkb:FOLD
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.amicusrx.com/
|
| gptkbp:bfsParent |
gptkb:Sol_Barer
gptkb:Sol_J._Barer gptkb:John_J._Crowley |
| gptkbp:bfsLayer |
7
|